AQUALUNG THERAPEUTICS, CORP
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $3.0Mattributed |
|---|---|
| Latest round | grant, $3.0M, 2023-09-01attributed |
| Founded | 2014 |
| Headquarters | JUNO BEACH, Florida, USA |
| Industry | bio |
| Stage | unknown |
| Website | aqualungtherapeutics.com |
Clinical-stage biopharma developing the ALT-100 monoclonal antibody for ARDS and progressive pulmonary fibrosis (interrupting eNAMPT/TLR4 signaling). Targets ARDS, fibrosis, and vascular-leak patient populations and pharma partners. FDA-cleared Phase 2a fibrosis study and PUERTA Phase 2a ARDS data presented in 2026 with NIH STTR support.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-09-01 | grant | $3.0M | undisclosed |
Detected tech stack
Afterpay, Sentry, Squarespace, Squarespace Commerce, Stimulus, parallax.js, Vercel Speed Insights, web-vitals, moment 0, @sentry/browser
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $3.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $3.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | aqualungtherapeutics.com, read 2026-05-05 |
| Description | self-reported | aqualungtherapeutics.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.